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Ovarian neoplasia comprises a heterogenous group of tumors with distinct clinicopathologic and 
molecular features and therefore assessment of potential risk factors should be tumor subtype-
specific. As part of on-going epidemiological investigations of ovarian neoplasia in Western 
Australia (WA), we performed an initial review of original pathology reports followed, in 
selected cases, by reassessment of histology material to optimize accurate diagnosis. Additional 
immunohistochemistry, often using antibodies unavailable at the time of initial assessment, was 
also performed as required. From an initial cohort of 1660 cases identified through the WA 
Cancer Registry (WACR), benign, non-epithelial, non-ovarian, miscellaneous and indeterminate 
cases were excluded. Also excluded were 33 cases that were reclassified as ovarian metastases 
rather than primary ovarian tumors. Following exclusions there remained 1321 borderline and 
malignant epithelial neoplasms. The diagnosis was considered accurate in 1186 cases (89.8%) 
based upon information in the initial pathology reports and clinical follow-up data but uncertain 
in 135 cases (10.2%). Histologic review was possible in 92 of the latter tumors leading to an 
amended diagnosis in 63 cases (68.5%). The most common types of diagnostic amendment were 
the reclassification of high-grade carcinomas of undifferentiated, endometrioid or transitional 
appearance as high-grade serous carcinoma, and the reclassification of most carcinomas of 
mixed epithelial type as ‘pure’ carcinomas. This review illustrated specific pitfalls in the 
diagnosis of ovarian epithelial neoplasia and helped to maintain the accuracy of the WACR. 
Accurate diagnosis will optimise further epidemiological studies assessing risk factors in specific 







Epidemiological studies play a key role in public health analysis including the identification of 
factors that predispose to, or may be protective towards, the development of certain tumors. In 
the gynecological context, for example, the risk of ovarian, fallopian tube and primary peritoneal 
(hereafter ovarian) neoplasia has been positively linked to certain hereditary factors (BRCA 
mutations and Lynch syndrome), infertility, pelvic inflammatory disease and in vitro 
fertilization, whereas hormonal contraception, parity and prior salpingectomy or tubal ligation 
appear to have a protective role (1-6). 
 A limitation of some epidemiological studies of ovarian neoplasia, particularly those 
conducted more than a decade ago, is that in many cases malignant epithelial tumors were 
grouped together and regarded as a single entity (epithelial ovarian cancer), and occasionally the 
same has applied to the analysis of borderline tumours. However, it is now recognized that 
ovarian tumors comprise a heterogenous group of neoplasms with differing clinical, histologic, 
immunophenotypic and molecular characteristics, and hence are likely to have different etiology 
(7-10). There are two major categories of borderline ovarian tumor (serous and mucinous) with a 
much less common subgroup exhibiting mixed epithelial (seromucinous) differentiation, and 
there are five major subtypes of ovarian carcinoma namely high-grade serous carcinoma 
(HGSC), low-grade serous carcinoma (LGSC), endometrioid carcinoma (EC), clear cell 
carcinoma (CCC), and mucinous carcinoma (MUCA). Carcinosarcoma, while less common, is 
also now regarded as a form of metaplastic carcinoma most often showing high-grade serous 
differentiation in its epithelial component (9). High-grade serous carcinoma accounts for 
approximately 65-70% of all ovarian carcinomas and hence studies of epithelial ovarian cancer 




implications regarding the investigation of etiological factors, possible preventative measures, 
and the optimal management of ovarian carcinoma since the identification of risk factors and 
treatment responses in the less common tumor subtypes may be obscured by the predominance 
of HGSC (11). 
 An additional difficulty presented by epidemiological analysis of relatively uncommon 
tumors such as ovarian carcinoma is that such studies generally cover a broad time period. This 
has the benefit of increasing the size of patient cohorts, thus maximising the power of statistical 
analysis. However, older histopathology diagnoses may not adhere to currently recognized tumor 
classifications and may lack the benefit of more recently developed ancillary diagnostic 
techniques such as immunohistochemistry (IHC) or molecular analysis (12,13). Furthermore, 
there may be significant changes in the interpretation of specific diagnostic scenarios, for 
example the appreciation that many tumors previously classified as high-stage ovarian MUCA 
are likely to represent primary non-gynecological malignancies metastatic to the ovary (14,15). 
 In a previous population-based study performed in Western Australia (WA) we found 
that women who had undergone hysterectomy with or without unilateral salpingo-oophorectomy 
(USO) had a reduced risk of ovarian cancer, confirming earlier reports (3). Unexpectedly, 
however, patients who had undergone USO without hysterectomy had a four-fold increased risk 
of ovarian cancer. This study has since been extended to include a larger cohort of approximately 
850,000 women in WA followed up for up to 45 years. Their detailed demographic, reproductive 
and surgical data obtained via linkage of routinely collected hospital, births and cancer registry 
information will be used to further clarify risk factors associated with the development of 
borderline or malignant epithelial ovarian neoplasms. However, in view of the potential 




review should be performed for identified cases, comprising at a minimum evaluation of the 
original diagnostic reports with re-examination of the original histologic material if required. In 
this report we discuss the results of this pathologic review, discussing amendments to the 
original diagnoses and the effects such review might have on epidemiological analysis. 
 
MATERIALS AND METHODS 
The study group comprised all women born in WA between 1945 and 1975 recorded in the WA 
Cancer Registry (WACR) to have a new diagnosis of borderline or malignant ovarian tumor 
between January 1982 and the end of June 2014. Given the heterogeneity of ovarian neoplasia 
one important aspect of this study was to ensure, as far as possible, that the tumors were 
correctly assigned in terms of pathological diagnosis. Therefore the pathology reports of the 
ovarian tumors (and those of any relevant earlier or subsequent cytology, biopsy or resection 
specimens) were reviewed by a gynecological pathologist (CJRS). In some cases, clinical follow-
up data were used to aid diagnostic categorization. For example, in cases of MUCA, long-term 
patient survival and the absence of any subsequently identified extra-ovarian mucinous neoplasm 
were considered strong support for the primary nature of the ovarian tumor. Cases in which the 
pathology report was unavailable were excluded. For the remaining cases, based upon the 
clinical information, the microscopic description of the tumor, the results of any 
immunohistochemical and molecular analysis, and available follow-up data, the original 
diagnosis was determined to be either confirmed or uncertain. The latter category included 
specific diagnostic scenarios (outlined below) which are known to cause difficulty in the 
diagnosis or subtyping of ovarian neoplasia. Review of the original histologic and/or cytologic 




then the cases were excluded. Additional IHC was performed in selected cases, often using 
antibodies that were not available at the time of initial diagnosis. In the histologically reviewed 
(uncertain) cases it was determined whether the original diagnosis was confirmed or amended, 
and the contribution of any additional IHC was also evaluated.    
 The indications for histologic review included the following: tumors initially reported as 
‘papillary adenocarcinoma’ or carcinoma/ adenocarcinoma, NOS;  bilateral tumors other than 
those of serous type; tumors in which there was earlier or subsequent identification of an extra-
ovarian neoplasm that may have been confused with a primary ovarian tumor (particularly 
mucinous and endometrioid carcinoma); all cases reported as grade 3 EC, primary transitional 
cell carcinoma (TCC), or carcinoma of mixed histologic type; cases in which there appeared to 
be a possible discrepancy between the microscopic description of the tumor, the results (or 
absence) of appropriate ancillary studies, and/or clinical follow-up information.    
 During the study period some serous carcinomas had been reported initially as 
moderately differentiated/ grade 2, based upon the ‘universal’ grading system for ovarian 
neoplasia (16) It is now accepted that HGSC and LGSC are different entities rather than different 
grades of one tumor type and thus the intermediate grade category for serous carcinoma is no 
longer applicable (17). In the current review it was clear from the original pathology reports that 
most serous carcinomas initially reported to be grade 2 were HGSC and these were reclassified 
as such. However, cases in which the distinction of HGSC and LGSC was impossible were 
reviewed. 
 The current pathologic review concentrated on the major subtypes of borderline and 
malignant epithelial tumors since these are the main focus of on-going epidemiological 




miscellaneous tumors were not examined in detail. However, cases with possible discordant 
diagnoses were reviewed whenever possible following the guidelines above. Furthermore, many 
of the tumors in these categories (particularly sex cord- stromal tumors) have been reviewed 
during recent unrelated studies (18-20).  
 The study received ethics approval (WA Department of Health HREC #2015/07, Curtin 
University HREC HR 41/2015). 
 
RESULTS 
In total, 1660 women were identified from the WACR database during the study period. The 
original pathology reports were unavailable in 42 cases and two spurious cases were identified 
(one a duplicated entry and the other a non-WA case that was reviewed as part of an independent 
study); these were excluded from further analysis. There were 84 malignant sex cord-stromal 
tumors, 56 malignant germ cell tumors and 25 miscellaneous rare neoplasms. Of the remaining 
1451 cases, 24 were considered to be benign and 33 were favoured to represent metastases to the 
ovary following reassessment. Twenty-one tumors remained of indeterminate subtype or origin 
usually because of limited diagnostic material. Fifty-two cases were excluded since they did not 
represent primary ovarian neoplasms. These included pathologically unrelated tumors such as 
retroperitoneal sarcomas which were captured in the initial search due to overlapping codes with 
ovarian neoplasia in the WACR. The process of case review and exclusion is outlined in Figure 
1. 
 Histologic and/or cytologic review was performed in 28 of the excluded tumors leading 
to a revision of the original diagnosis in 23 cases (82.1%), most commonly resulting in a final 




the latter cases the tumor origin was favored to be from the gastrointestinal tract, cervix and 
endometrium in nine, three and two cases, respectively, and the amended diagnoses were 
supported by additional immunohistochemical studies in 10 cases (Figs. 2 and 3). 
 Following the selection process described above 1321 borderline and malignant epithelial 
tumors of major subtypes remained in the main study group (Figure 1). The initial diagnosis was 
considered to be accurate in 1186 (89.8%) cases based upon the information presented in the 
original pathology report together with any relevant follow-up data. However, the diagnosis was 
considered uncertain in the remaining 135 (10.2%) cases almost all of which (n=129) were 
malignant. Slide review was performed in 92 (68.1%) of the uncertain tumors but was impossible 
in the remaining 43 (31.9%) cases because the original diagnostic slides were unavailable for 
examination. Following exclusion of the latter cases, there remained 1278 tumors including 419 
borderline tumors and 859 carcinomas. The number of cases with histologic review, the number 
with amended diagnosis, and the use of additional IHC for each tumor subtype are summarized 
in Table 2. 
Of the 92 uncertain cases that underwent histologic review, the original diagnosis was 
confirmed in 29 (31.5%) cases but was amended in the remaining 63 (68.5%) cases. The types of 
diagnostic amendment are summarized in Table 3. Across the histological spectrum, the most 
common causes of diagnostic amendment were changes in grade (arguably tumor subtype rather 
than grade in serous carcinomas), tumor categorisation (for example grade 3 EC being revised to 
HGSC), and reclassification of cases initially reported to be carcinomas of mixed histologic type. 
Only two of the latter cases in this study were confirmed upon review, both of which showed 
endometrioid and clear cell components. In the present analysis these were categorized according 




reported to be of mixed histologic type were considered to be ‘pure’ carcinomas, most often 
HGSC, with variable morphology following review (Table 3, Figs. 4 and 5).         
 
DISCUSSION 
Population-based epidemiological studies can identify factors that may increase or decrease the 
risks of developing specific types of tumor but analysis is complicated in ovarian neoplasia 
which encompasses a range of tumor subtypes most of which have distinct clinicopathologic 
features (7,8). Furthermore, there is evidence that risk factor associations vary according to the 
histologic subtype of ovarian neoplasia (13). For example, cigarette smoking has been linked to 
an increased risk of borderline and malignant ovarian mucinous tumors whereas salpingectomy 
or fallopian tube sterilisation procedures appear protective towards the development of ovarian 
EC and CCC, both of which are associated with endometriosis (21-23). Bilateral salpingectomy 
or salpingo-oophorectomy is also protective against HGSC with most such tumors now 
considered to arise within the fallopian tube (10). It is therefore important that any assessment of 
risk factors in ovarian neoplasia is subtype-specific, and this in turn necessitates accurate 
histologic diagnosis. In the present study we have evaluated pathological review as part of this 
process in a large series of tumors initially categorized as borderline or malignant ovarian 
neoplasms identified through the WACR.  
It is acknowledged that the present pathology review has several limitations. Firstly, a 
proportion of cases had to be excluded since the initial diagnostic reports could not be accessed, 
slides were unavailable for review, or because the final diagnosis remained uncertain. We also 
accept that histologic review was performed in very few borderline tumors and it is likely that at 




based upon the limited extent and mild nature of the atypia (24). Most significantly, in the great 
majority of cases (approximately 90%), acceptance of the final diagnosis was based only upon 
review of the pathology reports, albeit supported by clinical follow-up data and subsequent 
biopsy findings in many cases. Arguably, the ‘gold standard’ for pathological assessment would 
comprise complete histologic review of all tumors, ideally by a panel of pathologists. However, 
this would be impractical given the number of cases in studies such as this, and it would also be 
impossible to review those tumors (mainly from the earlier part of the study period) in which the 
original histologic material was no longer available.  
Despite these restrictions, we believe this has been a valuable review process and might 
serve as a practical approach for similar large epidemiological studies of neoplasia where 
complete pathological reassessment of all cases is not feasible. The selective histologic review in 
this study, with re-examination of original slides being prompted by an assessed likelihood of 
diagnostic error, was supported by the high proportion of amended diagnoses (82% of the 
reviewed excluded cases and 69% of the reviewed reclassified cases). For example, 33 metastatic 
tumours were identified most of which had been initially interpreted to be primary ovarian 
mucinous or endometrioid adenocarcinomas. The histologic difficulty posed by ovarian 
metastases has been well-documented, and the judicious use of IHC in this setting has also been 
emphasized (14,15) In the current series IHC was helpful in confirming the metastatic origin of 7 
colorectal tumours (including one low-grade appendiceal mucinous neoplasm) and the cervical 
origin of 3 tumors. Two of the latter occurred in patients with previously treated cervical 
adenocarcinomas but nonetheless the ovarian tumors were initially interpreted to be independent 
primary ovarian ECs. These cases presented prior to recent studies which have highlighted the 




diagnosis was facilitated by additional immunohistochemical analysis including the 
demonstration of diffuse p16 protein expression in all tumors. 
 The present review also demonstrated further areas in which there was a significant 
reclassification of specific tumor subtypes. Notably, only two of 16 carcinomas of mixed 
histologic type, both of which demonstrated admixed CCC and EC, were confirmed upon 
review. The remainder, most of which were reported initially as mixed HGSC/EC or mixed 
HGSC/CCC, were reclassified as pure HGSC with glandular (pseudo-endometrioid) morphology 
or clear cell change, respectively. As in the case of metastatic neoplasms, this reassessment was 
often supported by IHC analysis, using the characteristic differential staining patterns of such 
tumors with WT1, p53, p16, HNF1, napsin A, ARID1A and oestrogen receptor (28). Our 
findings support recent suggestions that genuine mixed epithelial tumors of the ovary are rare 
(9,10,29,30).  
 We also found that many tumors that were initially reported to be undifferentiated 
carcinomas, or high-grade carcinomas of uncertain origin (primary versus metastatic), were 
reclassified as HGSC. Likewise, although few tumors in this series had an initial diagnosis of 
grade 3 EC or TCC, most were reclassified as HGSC upon review with the initial diagnosis 
being confirmed in only 2/6 and 1/4 cases, respectively. As noted above, the distinction of 
endometrioid and serous carcinoma can be problematic when the latter exhibits a predominant 
glandular rather than papillary architecture, but immunophenotypic and molecular data 
demonstrate the serous nature of the majority of these cases (9,10,29,30). Our findings support 
the recent study by Lim and colleagues suggesting that ovarian grade 3 EC is uncommon, and 
that many cases previously categorised as such are in fact HGSC (31). Regarding the 




endometrioid-like and transitional-like (‘SET’) morphologic patterns in HGSC are associated 
with BRCA1 mutations, whether of germline or somatic origin, with potential implications 
regarding hereditary predisposition and therapeutic response (32,33).  
In summary, we describe the results of pathology report assessment and selective 
histopathologic review in a population-based series of more than 1500 ovarian tumors identified 
through a Cancer Registry. The review illustrated specific areas of diagnostic uncertainty, many 
of which led to case exclusion or to amended diagnosis, thus helping to maintain the accuracy 
and the utility of the Registry data. We believe this type of review is practical, and the methods 
could be applied in similar large-scale epidemiological studies to ensure that risk factor 
assessment in neoplasia is based upon accurate tumor subtyping. 
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FIGURE LEGENDS 
Figure 1. Outline of review process and case exclusion. 
Figure 2. Colonic adenocarcinoma metastatic to the ovary initially interpreted to be primary 
endometrioid carcinoma. A. The tumor shows well-formed glands and does not involve the 
ovarian capsule surface (left). B. Higher magnification demonstrating focal cribriform glandular 
pattern and more prominent mitotic activity and nuclear hyperchromasia than is typical of a low-
grade endometrioid carcinoma. C. Additional immunohistochemistry was characteristic of a 
primary colorectal neoplasm including diffuse cytokeratin 20 expression (depicted). 
Figure 3. Endocervical adenocarcinoma metastatic to the ovary initially interpreted to be primary 
endometrioid carcinoma. A. The tumor has a partly intracystic papillary architecture. Cribriform 
glands are focally present (upper left). B. Higher magnification showing glands lined by 
epithelium exhibiting more prominent nuclear atypia, mitotic and apoptotic activity than is 
typical of low-grade endometrioid carcinoma. Note focal apical cytoplasmic mucin (left). C. The 
tumor shows diffuse p16 protein immunoreactivity. 
Figure 4. High-grade serous carcinoma initially interpreted to be a mixed endometrioid and 




are prominent tumour-infiltrating lymphocytes. Immunohistochemistry shows diffuse expression 
of WT1 (B) and p53 protein (C) in all areas. 
Figure 5.  High-grade serous carcinoma initially interpreted to be a mixed clear cell and serous 
carcinoma. A. The tumor shows micropapillary (left and right) and clear cell-like (central) 
components. B. Higher magnification showing continuity between serous carcinoma (left) and 
cells with clear cytoplasm (right). Immunohistochemistry throughout was characteristic of high-
grade serous carcinoma including WT1 expression in the clear cell areas (depicted). 
